Interpace Biosciences, Inc. reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with net revenue decreasing by 18% to $38.7 million, down from $46.9 million in 2024. This drop was primarily attributed to the loss of reimbursement for the PancraGEN® test, which ceased coverage on April 24, 2025, leading to the discontinuation of the test and a subsequent restructuring plan that included workforce reductions. The company's operating income also fell to $4.1 million from $8.1 million in the previous year, reflecting the impact of reduced revenue and gross profit, which decreased to $24.1 million from $29.9 million.
In response to the loss of the PancraGEN® test, Interpace has shifted its focus to its molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2. The company aims to expand its market presence and improve reimbursement rates for these tests, which are critical for its revenue generation. The restructuring plan implemented in early 2025 resulted in approximately $0.7 million in severance costs, reflecting the company's efforts to align its operations with the new market realities.
Operationally, Interpace reported a total of 102 employees as of March 2026, maintaining a lean workforce in light of recent challenges. The company continues to rely heavily on Medicare reimbursements, which accounted for approximately 38% of its revenue in 2025. The loss of coverage for PancraGEN® has raised concerns about the sustainability of its revenue model, emphasizing the need for successful negotiations with payers to secure coverage for its remaining tests.
Looking ahead, Interpace expressed optimism about its growth potential in the molecular diagnostics market, which is projected to expand significantly in the coming years. The company is focused on increasing test volumes, securing additional insurance coverage, and developing new products to diversify its offerings. However, it remains cautious about the regulatory environment and the potential impact of future healthcare reforms on its operations and financial performance. The company is also exploring various strategic alternatives to enhance liquidity and support its growth initiatives.
About INTERPACE BIOSCIENCES, INC.
Interpace Biosciences specializes in esoteric molecular diagnostic testing and pathology services for cancer risk assessment. Its core offerings include genomic tests and assays for gastrointestinal, endocrine, and lung cancers, aiding physicians in diagnosis, risk stratification, and personalized treatment decisions. Serving hospitals, clinics, and labs, the company emphasizes clinical utility, reimbursement support, and innovative research to improve patient outcomes and reduce unnecessary surgeries.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.